These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7428144)

  • 1. A murine plasmacytoma model for screening active drugs for human myeloma.
    Hiramoto RN; Ghanta VK; Durant JR; Hiramoto NS
    Cancer Clin Trials; 1980; 3(4):395-402. PubMed ID: 7428144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma.
    Valeriote F; Grates H
    J Natl Cancer Inst; 1986 Jan; 76(1):61-5. PubMed ID: 3455743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
    Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
    Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of MOPC 104E myeloma in plateau phase.
    Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
    Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
    Ghanta VK; Jones MT; Woodard DA; Durant JR; Hiramoto RN
    Cancer Res; 1977 Mar; 37(3):771-4. PubMed ID: 851480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A methodological approach to the prediction of anticancer drug effect in humans.
    Durkin WJ; Ghanta VK; Balch CM; Davis DW; Hiramoto RN
    Cancer Res; 1979 Feb; 39(2 Pt 1):402-7. PubMed ID: 761212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of murine tumor models in cancer treatment research.
    Martin DS; Balis ME; Fisher B; Frei E; Freireich EJ; Heppner GH; Holland JF; Houghton JA; Houghton PJ; Johnson RK
    Cancer Res; 1986 Apr; 46(4 Pt 2):2189-92. PubMed ID: 3948188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human tumor testsystems: a new screening approach.
    Kraemer HP; Sedlacek HH
    Behring Inst Mitt; 1986 Jun; (80):103-12. PubMed ID: 3753367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
    Weiss L; Slavin G; Reich S; Sidi H; Slavin S
    Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse plasmacytoma: an experimental model of human multiple myeloma.
    Gadó K; Silva S; Pálóczi K; Domján G; Falus A
    Haematologica; 2001 Mar; 86(3):227-36. PubMed ID: 11255268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.